GENITOURINARY CANCERS

Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug.

The FDA has granted approval to the agent formerly known as 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.

In an interview with Targeted Oncology™, Sumtha K. Pal, discussed the most interesting research presented during ASCO Genitourinary Cancers Symposium.

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

Overall survival was prolonged with the addition of darolutamide to androgen-deprivation therapy and docetaxel in patient with metastatic, hormone-sensitive prostate cancer.

The phase 2 PERICLES trial of atezolizumab with or without radiotherapy in patients with stage IV cancer did not meet its primary end point of 1-year progression-free survival.

NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.

Health-related quality of life outcomes was more sustainable in patients with advanced renal cell carcinoma on nivolumab plus cabozantinib compared to sunitinib.

A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.

Three immune cell-related factors appear to impact response or lack of response to treatment with nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma.

Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.

Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT and percent change in lesion number may be associated with overall survival in patients with metastatic genitourinary malignancies.

An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.

Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.

Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.

Utilizing 18F-rhPSMA-7.3 imaging, detection rates for prostate cancer recurrence were favorable in the phase 3 SPOTLIGHT study.

In a subgroup analysis of the ARAMIS study, the safety and efficacy of darolutamide were not impacted by patients having comorbidities and receiving concomitant medications.

According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

In an interview with Targeted Oncology™, Clayton Lau, MD, discussed the impact of COVID-19 on managing genitourinary cancers.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.